- Molecular NameScopolamine
- SynonymNA
- Weight303.358
- Drugbank_IDDB00747
- ACS_NO51-34-3
- Show 3D model
- LogP (experiment)0.55
- LogP (predicted, AB/LogP v2.0)1.04
- pka7.6
- LogD (pH=7, predicted)0.2
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-1.04
- LogSw (predicted, AB/LogsW2.0)63.87
- Sw (mg/ml) (predicted, ACD/Labs)2.51
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds5
- TPSA71.53
- StatusFDA approved
- AdministrationTransdermal, ocular, oral, subcutaneous, intravenous, sublingual, rectal, buccal transmucousal, intramuscular
- PharmacologyA tropane alkaloid drug with muscarinic antagonist effects.
- Absorption_value93.0
- Absorption (description)N/A
- Caco_2-4.93
- Bioavailability27.0
- Protein binding10.0
- Volume of distribution (VD)1.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmScopolamine is extensively metabolized and conjugated with less than 5% of the total dose appearing unchanged in urine.
- Half life4.5 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAdverse reactions include Increased heart rate, Drowsiness, disorientation, dizziness, delirium, restlessness, tremors, locomotor difficulties, blurred vision, stinging, increased intraocular pressure, photophobia, conjunctivitis, local irritation including follicular conjunctivitis, vascular congestion, edema, exudates, eczematoid dermatitis (ophthalmic use), dry mouth, urinary retention, decreased respiratory rate.
- LD50 (rat)N/A
- LD50 (mouse)LD50=100 (intravenous)